文献速递中枢神经肿瘤放疗放疗物理与技术

外照射放疗与联网外照射加近距离放疗对多形性胶质母细胞瘤预后的比较分析:一项基于SEER人群的研究

Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study.
PubMed 文献 · Radiat Oncol · 2022-10-28

基于SEER数据库41,010例胶质母细胞瘤患者,比较外照射放疗(EBRT)与EBRT联合近距离放疗(EBRT+BT)的预后差异;EBRT+BT组中位总生存15个月、疾病特异性生存17个月均长于EBRT组(11个月、12个月),校正后EBRT+BT为独立保护因素(HR=0.84,95%CI[0.74,0.96],p=0.01)。

要点

  • EBRT+BT组中位总生存15个月、疾病特异性生存17个月,均长于EBRT组(11个月、12个月)。
  • 竞争风险模型和倾向性评分匹配后,仅高龄为独立危险因素,仅EBRT+BT为独立保护因素(HR=0.84,95%CI[0.74,0.96],p=0.01)。
  • 亚组分析中EBRT+BT在男性和局部切除患者中保护作用更明显(HR=0.81,95%CI[0.68,0.97],p=0.02;HR=0.82,95%CI[0.34,0.95],p=0.01)。

核心结论

  • EBRT+BT的治疗效果优于单纯EBRT,尤其在男性患者或接受局部切除的患者中;作者认为该发现可能为制定更好的胶质母细胞瘤放疗策略提供新证据。

研究设计与样本

  • 基于SEER数据库的队列研究,纳入41,010例符合条件的胶质母细胞瘤患者,分为EBRT队列和EBRT+BT队列。
  • 采用Kaplan-Meier分析和Cox比例风险回归确定总生存和疾病特异性生存的危险因素,并采用竞争风险模型和倾向性评分匹配消除潜在偏倚,同时进行亚组分析和交互检验。

主要发现

  • EBRT+BT组中位总生存15个月、疾病特异性生存17个月,均显著长于EBRT组(总生存11个月、疾病特异性生存12个月)。
  • 使用竞争风险模型和倾向性评分匹配后,仅高龄为独立危险因素,仅EBRT+BT为独立保护因素(HR=0.84,95%CI[0.74,0.96],p=0.01)。
  • EBRT对胶质母细胞瘤治疗具有普遍效果,EBRT+BT在男性亚组(HR=0.81,95%CI[0.68,0.97],p=0.02)和局部切除亚组(HR=0.82,95%CI[0.34,0.95],p=0.01)中保护作用更明显。

关键数值与推荐

  • EBRT+BT组中位总生存15个月、疾病特异性生存17个月;EBRT组中位总生存11个月、疾病特异性生存12个月。
  • 校正后EBRT+BT的HR=0.84,95%CI[0.74,0.96],p=0.01;男性亚组HR=0.81,95%CI[0.68,0.97],p=0.02;局部切除亚组HR=0.82,95%CI[0.34,0.95],p=0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Radiotherapy is one of the effective ways to treat glioblastoma multiforme (GBM). We aimed to explore the prognostic difference between external beam radiotherapy (EBRT) and EBRT combined with brachytherapy (EBRT + BT). METHODS: The GBM patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into two cohorts: the EBRT cohort and the EBRT + BT cohort. Kaplan-Meier (KM) analysis and Cox proportional hazards regression were used to determine the underlying risk factors for overall survival (OS) and disease-specific survival (DSS). And the competing risk model and propensity score matching (PSM) was adopted to eliminate potential biases. We also conducted subgroup analyses and interaction tests as well. RESULTS: There was a total of 41,010 eligible GBM patients. The median OS (15 months) and DSS (17 months) of the EBRT + BT cohort were significantly longer than that of the EBRT cohort (OS = 11 months, DSS = 12 months). After using the competing risk model and PSM, we found that only advanced age was the independent risk factor, while only EBRT + BT was the independent protective factor (HR = 0.84, 95%CI [0.74,0.96], p = 0.01). EBRT had universal effects in the treatment of GBM, and EBRT + BT had a more pronounced protective effect in the subgroups of males (HR = 0.81, 95%CI [0.68,0.97], p = 0.02) and local excision (HR = 0.82, 95%CI [0.34,0.95], p = 0.01). CONCLUSIONS: The therapeutical effect of EBRT + BT treatment is better than that of EBRT alone, especially in male patients or patients who have undergone local resection. Our findings may provide novel evidence to develop a better radiotherapy strategy for GBM patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang K, Ma Y, Chen G, et al. Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study. Radiat Oncol. 2022. PMID: 36307810. doi:10.1186/s13014-022-02141-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。